Contact Us

If your question is about a medical condition, then you should consult with a healthcare professional or, in the case of an emergency, call 911 immediately.

Standard business hours for CSL Behring are 8:30 am to 5:00 pm Eastern Time.

  • CSL Behring Headquarters

    Phone: 610-878-4000
    Fax: 610-878-4009

    Location: North America Headquarters

    Address: P.O. Box 61501
    1020 First Avenue
    King of Prussia, PA 19406 USA

  • Consumer Affairs

    For Consumer Information
    Phone: 888-508-6978
    Fax: 610-878-4008

    Medical Affairs

    Phone: 800-504-5434
    Fax: 610-878-4007

  • Adverse Events

    To Report an Adverse Event
    Phone: 610-878-4193
    Phone (After Business
    Hours): 866-915-6958

All fields are required.
 
   
Salutation:  
Suffix:  
First Name:  
Last Name:  
I am a:
  
This is my:
Address 1:  
Address 2:
City :  
State :
ZIP Code :  
Telephone Number   
E-mail Address :  
Confirm E-mail Address :  


I have questions about the information I am requesting and would like a CSL Behring representative to contact me by:
 
 
 
 

Type in the verification word in the box below and click "Submit."

Verification Word

Submit     Reset

Prior to submitting your information, please review our Privacy Policy

I would like to unsubscribe from this e-mail program.

Next: Important Safety Information »

Important Safety Information

Helixate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.